TY - JOUR
TI - Biologicals in childhood severe asthma: the European PERMEABLE survey on
the status quo
AU - Santos-Valente, Elisangela
AU - Buntrock-Dopke, Heike
AU - Abou Taam, Rola
AU - and Arasi, Stefania
AU - Bakirtas, Arzu
AU - Lozano Blasco, Jaime and
AU - Bonnelykke, Klaus
AU - Craiu, Mihai
AU - Cutrera, Renato
AU - Deschildre,
AU - Antoine
AU - Elnazir, Basil
AU - Fleming, Louise
AU - Frey, Urs
AU - Gappa,
AU - Monika
AU - Nieto Garcia, Antonio
AU - Hansen, Kirsten Skamstrup and
AU - Hanssens, Laurence
AU - Jahnz-Rozyk, Karina
AU - Jesenak, Milos and
AU - Kerzel, Sebastian
AU - Kopp, V, Matthias
AU - Koppelman, Gerard H. and
AU - Krivec, Uros
AU - MacLeod, Kenneth A.
AU - Makela, Mika
AU - Melen, Erik
AU - and Mezei, Gyorgyi
AU - Moeller, Alexander
AU - Moreira, Andre and
AU - Pohunek, Petr
AU - Minic, Predrag
AU - Rutjes, Niels W. P.
AU - Sammut,
AU - Patrick
AU - Schwerk, Nicolaus
AU - Szepfalusi, Zsolt
AU - Turkalj, Mirjana
AU - and Tzotcheva, Iren
AU - Ulmeanu, Alexandru
AU - Verhulst, Stijn and
AU - Xepapadaki, Paraskevi
AU - Niggel, Jakob
AU - Vijverberg, Susanne and
AU - Maitland-van der Zee, Anke H.
AU - Potocnik, Uros
AU - Reinartz, Susanne
AU - M.
AU - van Drunen, Cornelis M.
AU - Kabesch, Michael
JO - ERJ Open Research
PY - 2021
VL - 7
TODO - 3
SP - null
PB - EUROPEAN RESPIRATORY SOC JOURNALS LTD
SN - 2312-0541
TODO - 10.1183/23120541.00143-2021
TODO - null
TODO - Introduction Severe asthma is a rare disease in children, for which
three biologicals, anti-immunoglobulin E, anti-interleukin-5 and
anti-IL4RA antibodies, are available in European countries. While global
guidelines exist on who should receive biologicals, knowledge is lacking
on how those guidelines are implemented in real life and which unmet
needs exist in the field. In this survey, we aimed to investigate the
status quo and identify open questions in biological therapy of
childhood asthma across Europe.
Methods Structured interviews regarding experience with biologicals,
regulations on access to the different treatment options, drug
selection, therapy success and discontinuation of therapy were
performed. Content analysis was used to analyse data.
Results We interviewed 37 experts from 25 European countries and Turkey
and found a considerable range in the number of children treated with
biologicals per centre. All participating countries provide public
access to at least one biological. Most countries allow different
medical disciplines to prescribe biologicals to children with asthma,
and only a few restrict therapy to specialised centres. We observed
significant variation in the time point at which treatment success is
assessed, in therapy duration and in the success rate of
discontinuation. Most participating centres intend to apply a
personalised medicine approach in the future to match patients a priori
to available biologicals.
Conclusion Substantial differences exist in the management of childhood
severe asthma across Europe, and the need for further studies on
biomarkers supporting selection of biologicals, on criteria to assess
therapy response and on how/when to end therapy in stable patients is
evident.
ER -